Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance

Despite new and better treatments for juvenile dermatomyositis (JDM), not all patients with moderate severity disease respond adequately to first-line therapy. Those with refractory disease remain at higher ri...

Source: Pediatric Rheumatology - January 6, 2023 Category: Rheumatology Authors: Matthew A. Sherman, Hanna Kim, Katelyn Banschbach, Amanda Brown, Harry L. Gewanter, Bianca Lang, Megan Perron, Angela Byun Robinson, Jacob Spitznagle, Cory Stingl, Grant Syverson, Heather O. Tory, Charles H. Spencer and Stacey E. Tarvin Tags: Research article Source Type: research